<DOC>
	<DOCNO>NCT01994057</DOCNO>
	<brief_summary>For patient advanced NSCLC ( non small cell lung cancer ) , Individualized cancer therapy widely accept since success crizotinib administration base EML4-ALK fusion gene detection gefitinib erlotinib administration base EGFR-TKIs sensitive mutations.From clinical point view , individual difference often occur different patient , lead diverse effect ADR drug effect.Meanwhile , drug effect adverse drug reaction significantly influence pharmacokinetic factor pharmacodynamic factors.In research , try establish sensitive method detect sensitive mutation plasma discover correlation somatic germline mutation , trough concentration EGFR-TKI drug effect , association ADME-associated SNP , trough concentration EGFR-TKI adverse effect .Furthermore , vivo vitro research also crucial rational explanation clinical phenomenon .</brief_summary>
	<brief_title>A Retrospective Pharmacogenomics Research EGFR-TKIs , Gefitinib Erlotinib , Non-small Cell Lung Cancer ( NSCLC ) Treatment</brief_title>
	<detailed_description>The ADME-associated SNPs include CYP3A4 , CYP3A4 , CYP1A1 , CYP2D6 , ABCB1 , ABCG2 .The somatic mutation include EGFR , K-RAS , ALK</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>The main patient entry criterion include : age≥ 18 year ; histologically cytologically proved NSCLC ; Eastern cooperative oncology group performance status ( ECOG PS ) ≤2 ; adequate hematological , renal , hepatic function . uncontrolled systemic disease , evidence clinically active interstitial lung disease , chemotherapy time inclusion . The protocol approve Ethical Committee Cancer Center Sun YatSen University ( CCSU ) , write informed consent obtain form patient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Non-small cell lung cancer ( NSCLC ) ;</keyword>
	<keyword>EGFR-TKI ;</keyword>
	<keyword>Pharmacogenetics ;</keyword>
	<keyword>Precision medicine</keyword>
	<keyword>somatic mutation , germline mutation ;</keyword>
</DOC>